Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms (vol 13, 1223282, 2023)

被引：0
|
作者：
Grunwald, Viktor [1 ,2 ]
Powles, Thomas [3 ,4 ]
Eto, Masatoshi [5 ]
Kopyltsov, Evgeny [6 ]
Rha, Sun Young [7 ]
Porta, Camillo [8 ]
Motzer, Robert [9 ]
Hutson, Thomas E. [10 ]
Mendez-Vidal, Maria Jose [11 ]
Hong, Sung-Hoo [12 ]
Winquist, Eric [13 ]
Goh, Jeffrey C. [14 ,15 ]
Maroto, Pablo [16 ]
Buchler, Tomas [17 ,18 ]
Takagi, Toshio [19 ]
Burgents, Joseph E. [20 ]
Perini, Rodolfo [21 ]
He, Cixin [22 ]
Okpara, Chinyere E. [23 ]
McKenzie, Jodi [24 ]
Choueiri, Toni K. [25 ]
机构：
[1] Univ Hosp Essen, Clin Med Oncol, Essen, Germany
[2] Univ Hosp Essen, Clin Urol, Essen, Germany
[3] Queen Mary Univ London, Barts Canc Inst, London, England
[4] Queen Mary Univ London, Royal Free Hosp, London, England
[5] Kyushu Univ, Dept Urol, Fukuoka, Japan
[6] State Inst Healthcare Reg Clin Oncol Dispensary, Omsk, Russia
[7] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Dept Internal Med, Seoul, South Korea
[8] Univ Bari A Moro, Dept Biomed Sci & Human Oncol, Bari, Italy
[9] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[10] Texas Oncol, Med Oncol, Dallas, TX USA
[11] Hosp Univ Reina Sofia, Dept Oncol, Maimonides Inst Biomed Res Cordoba IMIBIC, Cordoba, Spain
[12] Catholic Univ Korea, Seoul St Marys Hosp, Dept Urol, Seoul, South Korea
[13] Univ Western Ontario, Dept Oncol, London, ON, Canada
[14] ICON Res, South Brisbane, Qld, Australia
[15] Univ Queensland, St Lucia, Qld, Australia
[16] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[17] Charles Univ Prague, Dept Oncol, Prague, Czech Republic
[18] Thomayer Univ Hosp, Prague, Czech Republic
[19] Tokyo Womens Med Univ, Dept Urol, Tokyo, Japan
[20] Merck & Co Inc, Global Clin Dev, Rahway, NJ USA
[21] Merck & Co Inc, Clin Res, Rahway, NJ USA
[22] Eisai Inc, Biostat, Nutley, NJ USA
[23] Eisai Ltd, Clin Res, Hatfield, England
[24] Eisai Inc, Clin Res, Nutley, NJ USA
[25] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
来源：
FRONTIERS IN ONCOLOGY | 2024年 / 13卷
关键词：
renal cell carcinoma; lenvatinib; pembrolizumab; sunitinib; bone metastases; liver metastases; lung metastases; sarcomatoid histology;
D O I：
10.3389/fonc.2023.1343027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results
    Eisen, T.
    Loembe, A-B
    Shparyk, Y.
    MacLeod, N.
    Jones, R. J.
    Mazurkiewicz, M.
    Temple, G.
    Dressler, H.
    Bondarenko, I.
    BRITISH JOURNAL OF CANCER, 2015, 113 (08) : 1140 - 1147
  • [42] A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results
    T Eisen
    A-B Loembé
    Y Shparyk
    N MacLeod
    R J Jones
    M Mazurkiewicz
    G Temple
    H Dressler
    I Bondarenko
    British Journal of Cancer, 2015, 113 : 1140 - 1147
  • [43] Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study
    Yan, X. Q.
    Yey, M. J.
    Zou, Q.
    Chen, P.
    He, Z. S.
    Wu, B.
    He, D. L.
    He, C. H.
    Xue, X. Y.
    Ji, Z. G.
    Chen, H.
    Zhang, S.
    Liu, Y. P.
    Zhang, X. D.
    Fu, C.
    Xu, D. F.
    Qiu, M. X.
    Lv, J. J.
    Huang, J.
    Ren, X. B.
    Cheng, Y.
    Qin, W. J.
    Zhang, X.
    Zhou, F. J.
    Ma, L. L.
    Guo, J. M.
    Ding, D. G.
    Wei, S. Z.
    He, Y.
    Guo, H. Q.
    Shi, B. K.
    Liu, L.
    Liu, F.
    Hu, Z. Q.
    Jin, X. M.
    Yang, L.
    Zhu, S. X.
    Liu, J. H.
    Huang, Y. H.
    Xu, T.
    Liu, B.
    Sun, T.
    Wang, Z. J.
    Jiang, H. W.
    Yu, D. X.
    Zhou, A. P.
    Jiang, J.
    Luan, G. D.
    Jin, C. L.
    Xu, J.
    ANNALS OF ONCOLOGY, 2024, 35 (02) : 190 - 199
  • [44] Belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma: Subgroup analysis of the phase 3 LITESPARK-005 study
    Albiges, Laurence
    Choueiri, Toni K.
    Peltola, Katriina
    de Velasco, Guillermo
    Burotto, Mauricio
    Suarez, Cristina
    Ghatalia, Pooja
    Iacovelli, Roberto
    Lam, Elaine T.
    Verzoni, Elena
    Gumus, Mahmut
    Stadler, Walter M.
    Kollmannsberger, Christian
    Melichar, Bohuslav
    Venugopal, Balaji
    Xing, Aiwen
    Perini, Rodolfo F.
    Vickery, Donna
    Rini, Brian
    Powles, Thomas
    ONCOLOGIST, 2024, 29 : S3 - S4
  • [45] Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
    Molina, Ana M.
    Hutson, Thomas E.
    Nosov, Dmitry
    Tomczak, Piotr
    Lipatov, Oleg
    Sternberg, Cora N.
    Motzer, Robert
    Eisen, Tim
    EUROPEAN JOURNAL OF CANCER, 2018, 94 : 87 - 94
  • [46] Retrospective Study of Real-World Treatment Patterns and Outcomes in Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Lenvatinib/Everolimus after Heavy Pretreatment
    Vogelzang, Nicholas J.
    Monnette, Alisha M.
    Wang, Yunfei
    Wan, Yin
    Robert, Nicholas J.
    Tannir, Nizar M.
    KIDNEY CANCER, 2021, 5 (04) : 189 - 197
  • [47] Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial
    Grimm, Marc-Oliver
    Oya, Mototsugu
    Choueiri, Toni K.
    Motzer, Robert J.
    Schmidinger, Manuela
    Quinn, David I.
    Gravis-Mescam, Gwenaelle
    Verzoni, Elena
    Van den Eertwegh, Alfonsus J. M.
    di Pietro, Alessandra
    Mariani, Mariangela
    Wang, Jing
    Thomaidou, Despina
    Albiges, Laurence
    EUROPEAN UROLOGY, 2024, 85 (01) : 8 - 12
  • [48] Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)
    Atkins, Michael B.
    Jegede, Opeyemi A.
    Haas, Naomi B.
    McDermott, David F.
    Bilen, Mehmet A.
    Stein, Mark
    Sosman, Jeffrey A.
    Alter, Robert
    Plimack, Elizabeth R.
    Ornstein, Moshe
    Hurwitz, Michael
    Peace, David J.
    Signoretti, Sabina
    Denize, Thomas
    Cimadamore, Alessia
    Wu, Catherine J.
    Braun, David
    Einstein, David
    Catalano, Paul J.
    Hammers, Hans
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (25) : 2913 - +
  • [49] The efficacy and safety of the combination of axitinib and pembrolizumab-activated autologous DC-CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study
    Song, Meng-Jia
    Pan, Qiu-Zhong
    Ding, Ya
    Zeng, Jianxiong
    Dong, Pei
    Zhao, Jing-Jing
    Tang, Yan
    Li, Jingjing
    Zhang, Zhiling
    He, Junyi
    Yang, Jieying
    Huang, Yue
    Peng, Ruiqing
    Wang, Qi-Jing
    Gu, Jia-Mei
    He, Jia
    Li, Yong-Qiang
    Chen, Shi-Ping
    Huang, Rongxing
    Zhou, Zi-Qi
    Yang, Chaopin
    Han, Yulong
    Chen, Hao
    Liu, Heping
    Xia, Shangzhou
    Wan, Yang
    Weng, De-Sheng
    Xia, Liming
    Zhou, Fang-Jian
    Xia, Jian-Chuan
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2021, 10 (03)
  • [50] A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma
    Kathryn E. Beckermann
    Amita Patnaik
    Ira Winer
    Winston Tan
    Babar Bashir
    Christos E. Kyriakopoulos
    Randy F. Sweis
    Marc Chamberlain
    Brian I. Rini
    Investigational New Drugs, 2024, 42 : 179 - 184
12345